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Summary The anti-cancer prodrug ifosfamide (IF) is metabolized by liver P450 enzymes by two alternative pathways. IF is activated to
4-hydroxy IF (4-OH-IF), which ultimately yields the alkylating mustard isophosphoramide, whereas IF N-dechlororethylation inactivates the
drug and produces the neurotoxic metabolite chloroacetaldehyde (CA). Both reactions are catalysed by multiple liver P450 enzymes in vitro
in isolated rat liver microsomes. The present pharmacokinetic study investigates the potential for modulation of these alternative pathways of
IF metabolism in vivo using the adult male Fischer 344 rat model. Rats were treated with IF alone or in conjunction with various P450 inducers
and inhibitors in an effort to improve the balance between drug activation and drug inactivation. Plasma concentrations, areas underthe curve
(AUC) and half-lives were calculated for 4-OH-IF and CA, allowing estimations of the extent of IF activation and deactivation/toxification.
Induction of liver P450 2B enzymes by 4-day high-dose phenobarbital (PB) pretreatment significantly decreased the fraction of IF undergoing
4-hydroxylation (AUC4OH-1 AUC4-OH IF+AUCCA), from 37% to 22% of total metabolism (P < 0.05), consistent with in vitro findings that the PB-
inducible P450 enzyme 2B1 plays a major role in IF N-dechloroethylation. Pretreatment with the P450 3A inducer dexamethasone
proportionally decreased the AUC for both IF metabolites, without any net impact on the fraction of IF undergoing metabolic activation. By
contrast, the P450 2B1 inhibitor metyrapone preferentially increased the AUC for the 4-hydroxylation pathway in 3-day low-dose PB-induced
rats, thereby increasing the total fraction of IF metabolized via the activation pathway from 36% to 54% (P < 0.05), whereas the P450
inhibitors orphenadrine and troleandomycin had no significant affect on AUC values. These findings demonstrate specific roles for P450 2B
and 3A enzymes in catalysing these pathways of IF metabolism in vivo, and demonstrate the potential for modulation of IF's alternative
metabolic pathways in a therapeutically useful manner. These studies also highlight several clinically relevant drug interactions that may
occur during concomitant administration of IF with drugs and othercompounds that modulate hepatic P450 enzyme levels.
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Ifosfamide (IF) is an anti-cancer alkylating agent with a broad
spectrum of activity, one that is different from the isomeric oxaza-
phosphorine cyclophosphamide (CPA) (Brock, 1996). Although
preclinical studies (Allen and Creaven, 1972; Goldin, 1982) and
clinical trials (Cabanillas et al, 1982; Morgan et al, 1982; Bramwell
et al, 1987) have shown a lack of complete cross-resistance
between these two drugs, their individual and respective advan-
tages and clinical applications are still debated (Kamen et al, 1995).
IF and CPA are both prodrugs requiring in vivo activation by liver
P450 enzymes to exert their cytotoxic activity (Sladek, 1994). The
initial P450-catalysed metabolic step forms a 4-hydroxy metabolite
and its ring-opened aldo tautomer, which ultimately decomposes to
yield an alkylating mustard (isophosphoramide mustard, in the case
of IF), which effects the bulk oftherapeutic action (Sladek, 1994).
However, despite similarities in chemical structure and mecha-
nisms of cytotoxicity, the in vivo disposition of CPA and IF differ
quantitatively in an important manner. Compared with CPA, the
initial P450-catalysed 4-hydroxylation ofIF proceeds more slowly,
and in some patients up to 50% of IF may be diverted towards an
N-dechloroethylation pathway (Kurowski and Wagner, 1993;
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Boddy et al, 1995). This alternative metabolic pathway is also P450
catalysed, and yields metabolites that are inactive (2- and 3-
dechloroethyl-IF) and neurotoxic (chloroacetaldehyde, CA) in a
1:1 molar ratio. CA, in particular, is believed to contribute to the
central neurotoxicity encountered exclusively with IF clinical use
(Goren et al, 1986; Aeschlimann et al, 1996) and may be related to
the depletion ofcerebral glutathione (Sood and O'Brien, 1996). IF
metabolism is thus characterized by a delicate balance between a
therapeutically beneficial activation pathway (4-hydroxylation)
and an undesireable drug inactivation/drug toxification pathway
(N-dechloroethylation).
IF 4-hydroxylation and N-dechloroethylation are both catalysed
by multiple enzymes belonging to the hepatic cytochrome P450-
linked mono-oxygenase system (Ruzicka and Ruenitz, 1992;
Chang et al, 1993; Weber and Waxman, 1993; Granvil et al, 1994;
Walker et al, 1994; Yu and Waxman, 1996). The identification of
those P450s that contribute specifically to these individual meta-
bolic pathways is of particular interest, given the large degree of
interindividual differences in the catalytic activities of specific
P450s seen in human liver samples (Shimada et al, 1994). These
interindividual differences in liver P450 profiles are likely to
contribute to the individual toxic and therapeutic effects resulting
from IF clinical use (Skinner et al, 1993; Boddy et al, 1996). In
vitro experiments using P450 form-selective antibodies and chem-
ical modulators have demonstrated that the enzyme P450 2B1 is
the major catalyst of IF N-dechloroethylation in phenobarbital
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(PB)-pretreated rat liver microsomes, whereas the constitutively
expressed P450s 2C1 1 and 2C6 make significant contributions to
IF N-dechloroethylation in untreated rats (Yu and Waxman, 1996).
Treatment of male rats with dexamethasone (DEX), a strong
inducer of liver P450 3A, decreased the extent of in vitro IF N-
dechloroethylation, from 47% to 24% of total metabolism, as
judged from initial rate studies using isolated liver microsomes
(Yu and Waxman, 1996). This suggests a specific role for P450 3A
in IF activation, and corroborates earlier studies in the rat liver
model (Weber and Waxman, 1993) as well as recent findings,
demonstrating a role for a corresponding human P450 enzyme,
P450 3A4, in IF activation in human liver microsomes (Chang et
al, 1993; Walker et al, 1994). These and other observations (Yu
and Waxman, 1996) further suggest that it may be possible to alter
the balance between IF 4-hydroxylation and IF N-dechloroethyla-
tion by use of appropriate P450-form-selective inducers and
inhibitors.
In addition to the P450 inducers DEX and PB, which preferen-
tially increase liver microsomal IF 4-hydroxylation (DEX) and IF
N-dechloroethylation (PB) respectively, several inhibitors of the
IF-metabolizing P450s can be considered for their potential with
respect to modulation of IF metabolism. The macrolide antibiotic
triacetyloleandomycin (TAO) forms covalent metabolic interme-
diate complexes by interaction with the active centres ofP450 3A
enzymes (Pessayre et al, 1981; Chang et al, 1994; Ono et al, 1996),
whereas the anti-Parkinson agent orphenadrine (ORP) forms anal-
ogous complexes with several liver P450s, including P450 2Cll
and P450 2B1 (Reidy et al, 1989; Roos and Mahnke, 1996). This
complexation, in turn, results in an inhibition of these P450s.
Inhibition ofP450 2B1 by non-covalent interaction with the haem
ligand metyrapone (MTP) has also been reported (Waxman and
Walsh, 1983; Halpert, 1995). Cytotoxic agents used for cancer
treatment are typically administered in combination regimens that
include multiple anti-cancer drugs, antibiotics, antiemetics and
other drugs, several of which are related to the P450 modulators
described above. Consequently, drug-drug interactions at the level
of P450-catalysed IF metabolism need to be considered. The
present pharmacokinetic study was designed to investigate the
potential ofP450 form-selective inducers and inhibitors for modu-
lation of IF metabolism in vivo in male Fischer 344 rats (a) in an
effort to potentially improve the balance between IF's alternative
metabolic pathways; and (b) to evaluate theirpotential for eliciting
drug interactions at the level ofP450-catalysed IF metabolism.
MATERIALS AND METHODS
Chemicals
IF was obtained from the Drug Synthesis and Chemistry Branch,
National Cancer Institute (Bethesda, MD, USA). 4-hydroperoxy-
IF was a gift from DrJ Pohl (ASTA Pharma, Bielefeld, Germany).
ORP hydrochloric acid, PB sodium and DEX were purchased from
Sigma Chemical (St Louis, MO, USA). TAO was kindly provided
by Pfizer (Brooklyn, NY, USA). MTP and other specialty chemi-
cals were of the highest grade commercially available and were
obtained from Aldrich Chemical (Milwaukee, WI, USA).
Animals
Male Fischer 344 rats (160-250 g; 7-11 weeks of age) were
purchased from Taconic (Germantown, NY, USA). Animals were
maintained in individual plastic cages under conditions ofconstant
temperature (22°C), lighting (12-h dark-light cycle) and humidity,
and provided with food and water ad libitum, in accordance with




For kinetic studies, rats were implanted with an indwelling
cannula (silicone medical grade/polyethylene tubing) in the right
jugular vein to allow blood sampling and drug administration.
Surgery was performed under ketamine (Ketaset 95 mg kg-') and
xylazine (Rompun 12 mg kg-') anaesthesia 3-4 days before the
kinetic experiment. After cannulation, a Rodent Infusion Set
obtained from Lomin (Quebec, Canada) was used to withdraw
blood samples at appropriate time intervals. Catheters were flushed
daily with heparinized saline (20 U ml-') to prevent clotting.
Animal treatmentand P450 modulation
Rats were separated into groups according to the drug pretreatment
schedules as follows: PB intraperitoneally (i.p.) given at a dosage
of 80 mg kg-' day-' for 4 consecutive days (PB80 group) or given
at 20 mg kg-' day-' for 3 days (PB20 group); PB at 80 mg kg-'
day-' as described above followed by TAO at 500 mg kg-' ofbody
weight injected on day 5 at 2 h before treatment with IF (PB+TAO
group); PB at 20 mg kg-' day-' i.p. for 3 days followed on day 4 by
(a) ORP at 75 mg kg-' as a single injection i.p. 2 h before IF admin-
istration (PB+ORP group) or (b) MTP at 30 mg kg-' as a single i.v.
injection 5 min before IF administration (PB+MTP group); DEX at
50 or 100 mgkg-' day-' suspended in corn oil and injected i.p. for 3
or 4 consecutive days (DEX50 and DEXIOO groups respectively).
PB, ORP and MTP were dissolved in saline (0.5 ml). TAO was
prepared fresh daily by a modification ofthe protocol ofArlotto et
al (1987). TAO was suspended in saline and 1 M hydrochloric acid
was then added at approximately 1:1 molar ratio until TAO
completely dissolved. The sample was then diluted in 0.9% saline
to the final required volume and the pH adjusted to pH 4 with 1 M
sodium hydroxide. Controls received saline alone in place ofORP,
MTP or TAO before IF injection (UT group, 'untreated'). IF was
administered to the rats via the jugular vein catheter at a dose of
100 mg kg-' body weight in 0.5 ml of0.9% saline solution. Blood
samples (0.5 ml) were drawn from the jugular vein and collected
on ice atthe following times: 5 minbefore IF administration (back-
ground metabolite value determination), then 4, 10, 20, 30, 40, 60,
90 and 120 min after IF dosing. Each sample was mixed with
heparin (20 U), and then divided between two Eppendorftubes that
were used to assay IF 4-hydroxylation and IF N-dechloroethyla-
tion. At each time point, the rats were given an injection of0.5 ml
of0.9% saline through the catheter to replace the volume ofblood
withdrawn.
Quantitation of IF 4-hydroxylation and
IF N-dechloroethylation
Determination ofIF4-hydroxylation
4-OH-IF was determined fluorometrically by the method of
Alarcon (1968) with modifications. Briefly, 260,l of each
heparinized blood sample was immediately mixed with 5 mM
semicarbazide, and then centrifuged at 16 000g for 4 min at room
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Figure 1 Influence of P450 inducers and inhibitors on IF 4-hydroxylation
and N-dechloroethylation in vivo. Plasma concentration x time profiles for
4-OH-IF and chloroacetaldehyde were determined after i.v. injection of IF at
100 mg kg-' in male Fischer 344 rats pretreated according to the schedules
described under Materials and methods. Data shown at each
pharmacokinetic sampling point are means ±s.d. values. (A) No
pretreatment, UT rats, n = 10; (B) PB20 rats, n = 3; (C) PB80 rats, n = 4;
(D) DEX at 50 mg kg-' day-' i.p. for 3 days (DEX rats n = 3). Pharmacokinetic
parameters were determined as described in Materials and methods. -U,
4-OH-IF; -*O-., CA
temperature. Plasma samples (100gl of supematant) were
removed and stored at -80°C until analysis. Plasma proteins were
precipitated by successive addition of40gl ofice-cold 5.5% (w/v)
zinc sulphate, 40gl of ice-cold saturated barium hydroxide and
20gl of ice-cold 0.01 M hydrochloric acid. Samples were
centrifuged for 15 min at 16 000 g, and 125 gl of the supernatant
was added to 67 gl of a solution containing 6 mg of 3-amino-
phenol and 6 mg of hydroxylamine hydrochloride dissolved in
1 ml of 1 M hydrochloric acid. Samples were heated at 90°C for
30 min in the dark, then allowed to cool to room temperature and
diluted with 408 pl of distilled water before reading the fluores-
cence (350 nm excitation and 515 nm emission) on a Shimadzu
RF15 spectrofluorophotometer. Standard curves with correlation
coefficient approximately 0.99 were generated using 4-hydro-
peroxy-IF (0-100gM) in 100 mm potassium phosphate (pH 7.4),
0.1 mm EDTA, 5 mm semicarbazide hydrochloride and distilled
water to a total volume of 100 pl. The recovery of 4-OH-IF from
plasma was approximately 60%, with a limit of detection of 100
pmol (1 gM metabolite in 100 pl).
Determination ofIFN-dechloroethylation
IF N-dechloroethylation was monitored by the formation of CA.
This P450-catalysed reaction proceeds via an initial a-carbon
hydroxylation and generates CA and dechloroethyl-IF in a molar
ratio of 1:1. CA present in the plasma samples was derivatized
with thiourea to produce 2-aminothiazole, which was assayed by
high-performance liquid chromatography (HPLC) after solid-
phase extraction by a modification of published methods (Yu and
Waxman, 1996). Briefly, a208-gl aliquot ofheparinizedblood was
immediately mixed with 1 mm formaldehyde to stabilize CA, and
then deproteinized with 25.2 pl of ice-cold 70% perchloric acid.
After centrifugation (16 000 g for 4 min) at room temperature,
140 pl of the supernatant was added to 21 pl of 100 mM thiourea.
The mixture was heated at 90°C for 1 h, at which time the deriva-
tization was maximal. The derivatized samples were stored at
-80°C until analysis (usually within 2 weeks). The 2-aminothia-
zole product was isolated using a 100-mg Bond Elut SCX cation-
exchange column (Varian), and then eluted, evaporated in vacuo in
a Speed Vac and analysed by HPLC on an Alltech Econosphere
C18 column with an absorbance detector operating at a wavelength
of 254 nm. The mobile phase consisted of 8% methanol in 10 mm
potassium phosphate buffer containing 0.05% triethylamine
pH 6.5 (flow rate, 1 ml min-'). The 2-aminothiazole derivative was
eluted from the HPLC column with a retention time of approxi-
mately 11 min and a detection limit ofapproximately 20 pmol. CA
was recovered with a yield of 78 ± 14% when authentic CA stan-
dard (3-15 nmol) was processed under the same assay conditions
in plasma. This external standard recovery was performed along-
side of each N-dechloroethylation determination, and used to
adjust the pharmacokinetic values. The addition of 1 mm
formaldehyde to stabilize the CA metabolite was found to be
important in obtaining this high recovery rate.
Enzyme assays
In vivo modulation ofCYP activities by PB and OR
For these experiments, livers were collected from adult male
Fischer 344 rats treated according to the PB+ORP pretreatment
schedule described above for the pharmacokinetic studies. To
investigate the time dependence of P450 2B1 inhibition by ORP,
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rats treated with the PB + ORP schedule were killed on day 4 either
2 h or 8 h after ORP i.p. injection. In rats treated with PB at 80 mg
kg-' day-' for4 days, only one time point for ORP inhibitory effect
was examined (rats killed 2 h after ORP injection). Untreated rats
were used as controls (UT group). In addition, another group of
rats was treated with ORP alone 2 h before being killed (ORP
group). Liver microsomes were prepared by a calcium precipita-
tion method (Waxman, 1991a), and then assayed for androstene-
dione hydroxylase activity by thin-layer chromatography (TLC)
(Waxman, 1991b). Incubation mixtures contained 0.1 M Hepes
pH 7.4, 0.1 mM EDTA, 25 ,ug microsomal protein, 10 nmol 14C-
labelled androstenedione, and 1 mm NADPH, in a total volume of
200 1l. Reactions were incubated for 10 min at 37°C in a water-
bath, extracted twice with 1 ml of ethyl acetate, concentrated to
dryness and then chromatographed on silica gel TLC plates devel-
oped with dichloromethane-absolute ethanol (97:3, v/v) followed
by chloroform-ethyl acetate (1:1, v/v). Metabolites were localized
by autoradiography and quantitated using a Molecular Dynamics
Phosphorimager and ImageQuant software.
ORP inhibition in vitro
The inhibition of PB-induced P450 2B1 activity by ORP was
evaluated in vitro by assaying PB-induced liver microsomes for
['4C]androstenedione 16p-hydroxylase activity in the presence of
600gM ORP, using the TLC assay described above.
Data analysis and statistics
Plasma concentrations of CA and 4-OH-IF declined monoexpo-
nentially when analysed on semilog plots ofconcentration vs time
for all of the rat treatment groups examined in this study. These
pharmacokinetic data were therefore approximated by a one-
compartment model (first-order kinetics). Area under the curve
(AUC) values were calculated by numerical integration using the
trapezoidal method, with the segment to infinity determined from
the last-measured plasma concentration value divided by the
elimination rate constant (Wagner-Nelson correction). The AUC
values reported here therefore correspond to AUC 0 to infinity
(Gibaldi and Perrier, 1982). Terminal elimination rate constants
(ke) were derived by linear regression analysis of logarithm of
(plasma concentration) vs time values for the last 4-7 time points
ofeach pharmacokinetic curve. Plasmahalf-lives foreach metabo-
lite were calculated from 0.693/ke values. The total metabolism of
IF was determined as the AUC value of CA (AUCCA) plus the
AUC value of 4-OH-IF (AUC4 OHIF). The fraction of IF
metabolized by 4-hydroxylation was then calculated based on
AUCO4-OH_F/(AUC4OHIF + AUCCA). In some cases, these values
were compared with a corresponding parameter based on plasma
peak value (Cmax) data, Cmax 4OH-1 (cmax 4-OH-IF + Cmax CA)- ANOVA
analysis was carried out on AUC, half-life andCm. values forboth
IFmetabolites, andforthe calculated fraction ofIF metabolized by
4-hydroxylation based on AUC values. For ANOVA results that
were significant for any parameter studied (Kruskal-Wallis test
statistics), two-group comparisons were made using a
Mann-Whitney test statistic, and P-values exceeding the 5% level
ofconfidence were deemed significant.
RESULTS
IF pharmacokinetics in uninduced rats (UT group)
The peak plasma concentration (Cmax) of4-OH-IF in untreated rats
was observed attmax = 4-10 min after IF injection (Figure IA). The
plasma concentration of4-OH-IF declined monoexponentially with
a half-life of40.8 ± 14.1 min (mean ± s.d.). The plasma concentra-
tion of CA peaked (tm,,) 20-30 min after IF administration, and
Table 1 Effect of different pretreatments on the pharmacokinetics of 4-OH-IF and CA in male Fischer 344 rats after i.v. administration at IF at 100 mg kg-'
Group 4-OH-IF CA Percent 4-OHa
Cmax t AUC Cmax tin AUC
(gM) (min) (gmmin) (jiM) (min) (gM min)
UT 46.7 ± 7.6 40.8± 14.1 2840±670 39.2 ± 8.5 66±10.2 4760±1250 37 ±9
(n= 10)
PB20 97.1 ± 17.2* 10.6 ± 2.8* 1770 ± 310* 74.3 +9.9*t 26.1 ±3.1 *t 3180± 650t 36± 9t
(n = 3)
PB80 114 ± 13.1 9.9 ± 2.1 1780 ± 290* 207.9 ± 35.6*t 20.3 ± 0.5*t 6560 ± 1380t 22 ± 4*t
(n=4)
PB20+OR 69.2 ± 11.7 13.3 ±2 1690 ±490 55.5± 8.4 34.1 ± 6.4 3340 ±720 34± 6
(n =5)
PB20+MTP 34.9 ±7.6*t 48.6 ± 11.1t 3110 ± 660t 23.1 ± 6.2*t 47.4 ± 10.2*t 2610 ±560* 54 ±7*t
(n =5)
PB80+TAO 94.5 ± 6t 14 ± 1.2t 2090 ± 280 171.5 + 32.5 32.7 ± 3.5t 8600 ± 500* 20 ± 3*
(n = 3)
DEX 86.2 ± 4.8* 14.3 ±4.8* 1920±260* 59.1 ± 14.2 29± 4.4* 3530±1290 36 ± 7
(n = 3)
IF was administered at 100 mg kg-' to male Fisher 344 rats given various pretreatment schedules as detailed under Materials and methods. Control animals
(UT rats) received saline in place of pretreatment drugs. *Significantly different from UT (P< 0.05). tSignificantly different from PB20 (P < 0.05). tSignificantly
different from PB80 (P < 0.05). In the PB+ORP and PB+MTP groups, ORP and MTP were given in the context of the PB20 pretreatment regimen. In the
PB+TAO group, TAO was given in the context of the PB80 pretreatment regimen. n, number of individual rats/treatment group. Data shown are means ± s.d.
values. aCalculated based on AUC4OH IF/AUC4OH+AUCCA)


































Figure 2 Influence of the P450 inhibitors ORP and MTP on IF
pharmacokinetics in PB20rats. Rats were pretreated with PB according to
the PB20induction schedule, and then were given either ORP or MTP before
asingle i.v. injection of IF, as described in Materials and methods. Shown are
plasma concentration-time profiles (mean ± 0.5 s.d.) for 4-OH-IF (A) and for
CA (B). Pharmacokinetic profiles are based on n =3 rats per group (PB20
rats) or n =5 rats per group (PB20+ORP and PB20+MTP groups). -{-,
PB20; .*e., PB20+ORP, *0.-, PB20+MTP
decayed with a half-life of66± 10.2 min(Table 1). The mean AUC
values for 4-OH-IF and CA were, respectively, 2840 and 4760 JIM
min in untreated rats, corresponding to 37% metabolism through
the 4-hydroxylation pathway and 63% metabolism via the N-
dechloroethylation pathway (Table 1).
Effects of PB induction and impact of different PB
schedules on IF pharmacokinetics
Pretreatment with PB using either of two induction schedules
(PB20 and PB80 groups) significantly increased the plasma peak
concentrations and decreased the apparent half-lives of both 4-
OH-IF and CA, compared with untreated rats (P < 0.05) (Table 1,
Figure lB and C). PB pretreatment significantly shortened tmax)
particularly forCA[timax = 30 min in UTrats (Figure IA) vs tmax =
4 min (Figure lB and C)]. PB treatment also effected a 40%
decrease in AUC4OHWIF when compared with a control group
(P < 0.05). Similar changes in these 4-OH-IF pharmacokinetic
parameters were observed at both PB dosage and induction sched-
ules (Table 1). By contrast, IF N-dechloroethylation showed a
more substantial dependence on PB schedule. In rats pretreated for
4 days at the higherPB dose (PB80group), the plasma Cmax forCA
was increased to a much greater extent than in rats pretreated with
the lower dose and shorter schedule (PB20 group) (five- vs two-
fold increase, P < 0.05). The decrease in CA half-life was corre-
spondingly greater in the PB80 rats (t,12 = 20.3 min in PB80 rats
vs 26.1 min in PB20 rats, P < 0.05; compare with t,12 = 66 min in
UT rats) (Table 1, Figure lB and C).
AUCCA was increased by 40% in PB80 rats compared with
untreated rats, but this increase did not reach statistical signifi-
cance (P = 0.09). This change in AUCCA accounts for the overall
decrease in the total fraction ofIF metabolized by the 4-hydroxyl-
ation pathway (based on AUC values) in the PB80 treatment
group compared with untreated rats (22 vs 37%, P< 0.05)
(Table 1). Total metabolite formation represented by AUCtotal
(AUC4OHIF+AUCCA) decreased from 7600gM min in UT rats to
4950gM min in PB20 rats. This decrease primarily reflects
decreases int1/2 for both 4-OH-IF and CA, which are only partially
compensated forby increases in the corresponding Cmax values. By
contrast, total metabolite AUC was increased in rats treated with
the PB80 induction regimen ([AUCtotal = 8340gmM min for PB80
group, and 10690gM minin the case ofPB80rats treated with the
CYP3A inhibitor TAO (see below)]. These increases largely
reflect an increase in AUCCA: two- to threefold decreases int1/2 for
CA were more than compensated by approximately four- to five-
fold increases in Cmax for CA in both PB80 rat groups (Table 1).
Effects of P450 inhibitors ORP and MTP on IF
pharmacokinetics in PB-induced rats
Pharmacokinetic profiles for 4-OH-IF and CA in PB20 rats given
the P450 inhibitors ORP or MTP are shown in Figure 2. ORP
given to PB20 rats by i.p. injection at 75 mg kg-' and 2 h before IF
caused an apparent 25% reduction in the Cmax of CA (P = 0.004)
and an apparent increase (approximately 30%) in CA's half-life in
comparison with PB20 rat controls (Table 1). However, these
effects were not significant (P = 0.1). A decrease was also
observed in 4-OH-IF Cmax,but did not reach statistical significance
(Table 1). ORP treatment of PB20 rats did not change the AUC
values of either CA or 4-OH-IF and did not alter their corre-
sponding tmax values compared with PB-induced rats.
MTP given as a single i.v. injection to PB20rats 5 minbefore IF
administration substantially reversed the pharmacokinetic changes
in IF metabolism observed in response to the PB20 induction
schedule (Figure 2 and Table 1). Inparticular, 4-OH-IFCmaxvalues
were decreased by MTP from 97.1 ± 17.2 to 34.9 ± 7.6gM
(P < 0.05) without a change in tmax (4 min), whereas the Cm. for
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CA was similarly decreased and the tmax was delayed to 60 min
after IF administration, as shown in Figure 2B. MTP increased
significantly the AUC4OH FA compared with PB20 controls (3110
vs 1770 ,UM min). Moreover, MTP decreased significantly AUCCA
compared with untreated rats (Table 1). Overall, the total fraction
of IF undergoing activation via the 4-hydroxylation pathway was
increased, asjudged by AUC values, from 37% to 54% (P < 0.05).
Effects of DEX pretreatment
As shown in Figure ID, treatment of rats with DEX at 50 mg kg-'
for 3 days before IF administration resulted in up to a two-fold
increase in Cmax ofboth 4-OH-IF and CA compared with untreated
controls. Half-lives of both 4-OH-IF and CA were also
significantly decreased, by two- to threefold, to 14.3 + 4.8 and
29 ± 4.4 min respectively (P < 0.05) (Table 1), whereas tmax values
were shortened for both metabolites (4 and 10 min for 4-OH-IF
and CA respectively). Based on AUC values, the fraction of IF
undergoing activation via 4-hydroxylation did not change upon
DEX pretreatment (36 vs 37%, P = 0.8), AUC4OHWIF and AUCCA
showing proportional decreases in DEX-treated rats compared
with untreated controls. In rats pretreated with DEX at 100 mg
kg-' for 4 days, variations for 4-OH-IF and CA AUC values, half-
lives and C values were similar to the ones found for DEX50
rats (results not shown).
Effects of TAO inhibition in rats pretreated with PB
TAO is a P450 3A-selective inhibitor in several species, including
rat and human [e.g. Chang et al (1994)] and has been shown to
inhibit P450 3A-dependent digitoxin toxicity in vivo when given
to rats at 500 mg kg-' (Arlotto et al, 1986). In PB80 rats given
TAO 2 h before IF, the C values ofboth 4-OH-IF and CA were
somewhat decreased compared with rats treated with PB alone.
However, only the C of 4-OH-IF was decreased significantly
(17% decrease, P < 0.05). Based on plasma half-lives, CA and 4-
OH-IF both had significantly slower elimination rates in response
to TAO treatment of the PB80 rats (P < 0.05) (Table 1), whereas
tmax values were not altered. AUCCA was increased by TAO to a
somewhat larger extent (30% increase; 8600 vs 6560gM min, P =
0.039) than AUC4OH IF (17% increase; not statistically significant)
compared with PB treatment alone. Overall, however, TAO
had no net impact on the total fraction of IF metabolized by the
4-hydroxylation pathway.
In vitro microsomal assays
PB treatment was associated with a fivefold induction (PB20
regimen) or a 7.5-fold induction (PB80 regimen) of androstene-
dione 16,B-hydroxylase activity measured in isolated liver micro-
somes (Figure 3). This increase reflects the PB dose-dependent
induction of P450 2B1, which catalyses androstenedione 16i-
hydroxylation at a high rate (Waxman et al, 1983) and is the
predominant catalyst ofthis PB-induced liver microsomal enzyme
activity (Waxman and Azaroff, 1992). ORP treatment ofPB20 rats
in vivo at 75 mg kg-', either 2 h or 8 h before removal of the liver
and isolation of liver microsomes did not, however, result in a
decrease in this microsomal P450 2B1 activity. By contrast, in
vitro addition of ORP at 600 ,UM to either PB20 microsomes or
PB20, 2 h ORP microsomes inhibited microsomal androstene-
dione 16p-hydroxylase activity down to the level of uninduced
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Figure 3 Effect of in vivo and in vitro ORP treatment on hepatic microsomal
androstenedione 16,B-hydroxylase activity. Adult male Fischer 344 rats were
treated according to the following schedules: UT (untreated) rats and PB20
rats, n = 3; PB80 rats, n = 2; ORP at 75 mg kg-' i.p. given to PB20 rats
that were killed either 2 h or 8 h after ORP administration, as indicated
(+ORP/2 h, n = 4; +ORP/8 h, n = 3); ORP at 75 mg kg-1 i.p. given to PB80
rats (+ORP/2 h, n = 3). Microsomal androstenedione 161-hydroxylase activity
was determined as described in Materials and methods. Androstenedione
163-hydroxylase control activity was determined in triplicate in untreated rats:
0.47 ± 0.12 nmol min-1 mg-1. Androstenedione 16p-hydroxylase activity was
also measured following in vitro addition of 600gM ORP to untreated liver
microsomes, to PB20-induced liver microsomes or to PB20+ORP/2 h
microsomes (*PB20), as shown on the right
liver microsomes (.75% inhibition) (Figure 3). This inhibitory
effect of ORP was not specific to androstenedione 16,-hydroxyl-
ase activity, however, as CYP3A-dependent androstenedione 6p-
hydroxylase activity was also inhibited, albeit to a lesser extent
(approximately 40% inhibition) in the same in vitro microsomal
incubations (data not shown).
DISCUSSION
A major limitation in the use of cancer chemotherapeutic drugs is
the relatively narrow therapeutic window between the dose of a
drug that is effective and that which results in excessive host toxi-
city. This balance can be altered by many factors, including drug
metabolism. IF metabolism has been described as a precarious
balance between an activation (4-hydroxylation) and atoxification
pathway (N-dechloroethylation) (Sladek, 1994; Brock, 1996),
both ofwhich are catalysed by liver P450 enzymes. Consequently,
modulation of these alternative and competing pathways of IF
metabolism provides a potential opportunity to improve IFclinical
use. In vitro studies in the rat liver model have identified the
specific, individual P450s that contribute to IF metabolism (Weber
and Waxman, 1993; Yu and Waxman, 1996). Distinct, but overlap-
ping, subsets of liver P450 enzymes have been shown to catalyse
IF activation via 4-hydroxylation compared with IF N-
dechloroethylation (Yu and Waxman, 1996). The primary goal of
the present study was to determine whether the total fraction of IF
metabolized by the 4-hydroxylation pathway can be modulated in
vivo by using P450 inducers and inhibitors, as predictedby in vitro
studies (Yu and Waxman, 1996).
As is seen in humans (Kurowski and Wagner, 1993; Boddy et al,
1995), the present pharmacokinetic analysis in the uninduced rat
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model indicated that a major fraction (63%) of IF was metabolized
by the N-dechloroethylation pathway, as indicated by AUC values.
This high-degree of N-dechloroethylation reflects the compara-
tively low catalytic efficiency for IF 4-hydroxylation exhibited by
the individual liver P450 enzymes. Pretreatment of rats with PB
results in a substantial induction of P450 2B1 and its associated
androstenedione 16Ji-hydroxylase activity, and resulted in more
rapid liver metabolism, as indicated by higher peak plasma
concentrations (Cmax) and shorter tmax values for both 4-OH-IF and
CA in PB-pretreated rats. Thus, PB pretreatment stimulates more
rapid metabolism of IF by both pathways, thus verifying in an in
vivo model earlier in vitro findings that the PB-inducible P450
2B1 is a major catalyst of both IF metabolic pathways (Yu and
Waxman, 1996). This more rapid formation of4-OH-IF and CA, in
the case of both PB-pretreated rats and DEX-pretreated rats, in
turn, results in shorter apparent half-lives for both IF metabolites.
The significant increase in Cmax for both 4-OH-IFA and CA upon
PB treatment could lead to alterations in IF's therapeutic activity
and/or toxicity owing to the importance of this pharmacokinetic
parameter in determining biological effects. Although AUC values
for reactive metabolites are generally considered to provide a reli-
able pharmacokinetic measure of drug exposure, threshold effects
could modify the impact and the effectiveness ofdrug exposure. In
the case of IF, the total time of exposure to an active or toxic
metabolite (e.g. 4-OH-IF or CA) at a concentration above a given
threshold could be of major therapeutic or toxicological signifi-
cance, in which case the observed effects of P450 modulators on
Cmax and t12 values for 4-OH-IF and CA (Table 1) take on added
significance.
PB exhibited dose-dependent effects on the alternative path-
ways of IF metabolism, with the higher dose, 4-day PB induction
regimen increasing CA production disproportionate to IF 4-
hydroxylation when compared with the lower dosage, 3-day PB
schedule (Table 1 and Figure lB and C). This finding is consistent
with the correspondingly larger increase in IF N-dechloroethyla-
tion metabolic rates observed in liver microsomes isolated from
rats pretreated with the same PB80 induction schedule (Yu and
Waxman, 1996). These results suggest a threshold effect of PB
dosage above which PB preferentially augments IF N-
dechloroethylation at the expense of the IF 4-hydroxylation
pathway. This differential dose-dependent effect of PB on the
alternative IF metabolic pathways is consistent with PB having
pleiotropic effects on liver metabolism (Waxman and Azaroff,
1992) and suggests that P450 enzymes with distinct dose depen-
dencies for PB induction contribute to these alternative PB-
inducible metabolic pathways.
MTP is a haem ligand and P450 inhibitor with some specificity
for P450 2B1 (Waxman and Walsh, 1983). When given to PB-
induced rats, MTP stimulated a significant and beneficial increase
in IF 4-hydroxylation relative to IF N-dechloroethylation, giving a
total fraction of IF metabolized via the activation pathway of54%
(vs 36-37%, P < 0.05, for either untreated or PB-treated rats). The
inhibition ofP450 2B1 by MTP results from its ability to serve as
a non-covalent ligand for the P450 haem prosthetic group,
precluding investigations of its in vivo inhibitory effects using
liver microsomes isolated from MTP-treated rats. In contrast, the
anti-Parkinson drug ORP, reported to be striking inhibitory toward
P450 2B1-dependent androstenedione 16p-hydroxylase activity in
vitro using PB-induced rat liver microsomes (Reidy et al, 1989)
and also inhibitory to P450 2C11 in in vivo experiments using
uninduced adult male rats (Roos and Mahnke, 1996), proved to be
inefficient in vivo for limiting the fraction of IF undergoing N-
dechloroethylation. Inhibition by ORP was observed when this
P450 inhibitor was added to liver microsomes in vitro but was not
observed in liver microsomes isolated from PB-induced rats given
ORP either 2 or 8 h before killing. ORP is reported to inhibit P450
2B1 by formation of a metabolic intermediate complex (Reidy et
al, 1989); such a complex may also be formed in vivo, but could
dissociate during the isolation of liver microsomes. Moreover, the
time course for the effects of ORP on liver P450 may be crucial,
given the difficulty in detecting an inhibitory complex in isolated
liver microsomes either 14 h (Reidy et al, 1989) or 2-8 h (as in our
study) after ORP injection (also see Roos and Mahnke, 1996). This
could explain the lack of effect of PB20+ORP on the net extent of
IF N-dechloroethylation in the present study. Although ORP addi-
tion in vitro to liver microsomes prepared from rats pretreated
with the PB20 induction schedule did restore a certain level of
androstenedione 16[-hydroxylase inhibition, this inhibitory effect
should be cautiously interpreted, given that significant inhibition
was also observed, albeit to a lesser extent, for CYP3A-dependent
androstenedione 6,B-hydroxylase activity. Indeed, ORP might lack
complete P450-form specificity as other investigators have
recently reported ORP inhibition of P450 3A activities (Roos and
Mahnke, 1996; Royer et al, 1996).
In several species, including humans, the macrolide antibiotic
TAO has found widespread use as a selective inhibitor of
cytochrome P450 3A enzymes (Halpert, 1995). Treatment of PB-
induced rats with TAO before IF increased AUCCA by 30%
compared with PB80 rat controls, but, overall, TAO did not have a
significant impact on the fraction ofIF metabolized via the activa-
tion pathway. These findings are consistent with our earlier
conclusion, based on in vitro studies, that P450 3A enzymes
contribute only partially to both IF metabolic pathways in PB-
induced rat liver microsomes, such that the P450 3A inhibitor TAO
has no significant impact on the balance between these two
pathways in liver microsomal studies (Yu and Waxman, 1996).
However, our in vitro studies had predicted that the P450 3A
inducer DEX would increase the fraction of IF metabolized by the
activation pathway substantially (Yu and Waxman, 1996). Such an
increase was not observed in the present in vivo study, independent
of whether the calculation of fraction of IF metabolized by the
activation pathway was based on AUC values or on Cmax values.
That DEX did effectively induce liver P450 metabolism in these
animals was evidenced by the increase in Cmax and decrease int1,2
seen for both IF metabolites (Table 1). Further studies are required
to understand the factors that contribute to these apparent discrep-
ancies between the effects of DEX on IF metabolism in vivo (this
study) and in isolated liver microsomes (Yu and Waxman, 1996).
It is apparent from the present investigation that several
common P450 inducers and inhibitors can have a major impact on
the pharmacokinetics and metabolism of IF, with some of these
modulators suggesting potentially useful approaches to increasing
the therapeutic index ofIF in vivo. Even though a similar subset of
P450 enzymes may catalyse both IF metabolic pathways, as advo-
cated by Walker et al (1994) based on studies ofP450 3A4 metab-
olism in human livermicrosomes, the present study suggests that it
may nevertheless be possible to modulate in vivo the balance
between the alternative and competing pathways ofIF metabolism
by using a suitable combination of P450 form-selective inhibitors
and inducers. The potential effectiveness of such a modulation
strategy is best illustrated in the present rat model studies by the
combination of MTP inhibition with PB induction. That some of
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the P450 modulators examined in this study are commonly admin-
istered with cytotoxics for cancer patients [e.g. DEX as an
antiemetic (Levitt et al, 1993)] should be considered more seri-
ously by clinicians in view of these in vivo and in vitro results.
Chemotherapeutic agents such as IF are commonly administered
in combination regimens, involving other anti-cancer drugs and
immunomodulators, and both groups of compounds have demon-
strated potential to alter liver P450 profiles and enzyme levels
(LeBlanc and Waxman, 1990; LeBlanc et al, 1992; Chang and
Waxman, 1993; Royer et al, 1996; Tapner et al, 1996). Many of
these drugs are also subject to P450 metabolism or may serve as
P450 inducers and inhibitors, and thus might have a significant
impact on the metabolism and therapeutic efficacy of IF. Of note,
most of the results from the present in vivo study confirm earlier
results based on in vitro studies using rat livermicrosomes (Yu and
Waxman, 1996). Thus, in vitro enzymatic tests for the metabolism
of IF do, indeed, have predictive value in the intact rat.
Nevertheless, it should be noted that in vitro enzymatic tests rely
on initial rate kinetics, whereas for interpretation of our results of
in vivo IF metabolism we have relied primarily on AUC values,
which are considered the best single parameter for evaluating the
efficacy of a cytotoxic schedule, both at the preclinical and at the
clinical level (Collins et al, 1990). By contrast, peak plasma
concentration values are expected to more faithfully reflect the
initial rate of metabolite formation, corresponding to the specific
activity determined in the in vitro microsomal experiments.
Although the present study suggests ways in which drugs and
chemicals that act as P450 inducers and inhibitors may be used to
improve the therapeutic balance of IF metabolism, our findings
also highlight the potentially significant impact of xenochemicals
that may alter IF metabolism to either increase its toxicity or
compromise its therapeutic activity. In particular, IF metabolism
and pharmacokinetics may be sensitive to unintentional alteration
by concomitantly administered drugs or dietary components that
modulate P450 2B or P450 3A activity (Walter-Sack and Klotz,
1996). Pharmacokinetic monitoring of IF and its metabolites may
therefore be useful in further delineating the extent to which such
interactions occur and theirclinical significance in cancerpatients.
Studies with hepatic P450s have shown that P450-catalysed
drug metabolism and the regulation of the expression of these
xenobiotic-metabolizing enzymes can sometimes be quite
different in humans compared with that found in experimental
animals (Guengerich, 1989; Wrighton and Stevens, 1992; Nelson
et al, 1996). In some cases, different strains within the same
species may show differences in the levels of expression of
specific P450s (Kraner et al, 1996). Several human P450s have
unique enzymatic activities and specificities not found in rats or
mice (Gonzalez et al, 1991). Furthermore, corresponding P450
enzymes may perform different metabolic functions in different
species, hampering the extrapolation to humans ofresults obtained
in laboratory animals. This point is particularly important to note,
since rodents and rodent-based systems are typically used to test
drugs under development for human use. Providing essential
pharmacokinetic information, the rat and other animal models
contribute to rational drug schedule development, although there
is no guarantee that human cancer patients will handle a drug in
the same way as the animal species (Lin, 1995; Cashman et al,
1996). Therefore, a more complete understanding of these species
differences must be obtained before extrapolating results to
humans. However, with the recent and promising development of
P450-based gene/transfer therapy studies for cancer treatment with
drugs such as IF and CPA (Wei et al, 1994; Chen and Waxman,
1995; Chen et al, 1996; 1997), the rat model might prove to be
valid and very useful for predicting IF metabolism in humans.
Ultimately, these studies may contribute to a more detailed under-
standing of the capacity of individual patients with respect to
hepatic P450-catalysed IF metabolism and how co-administered
drugs alter liver P450 profiles.
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ABBREVIATIONS
IF, ifosfamide; CPA, cyclophosphamide; P450 or CYP,
cytochrome P450; 4-OH-IFA, 4-hydroxy-IF; CA, chloracetalde-
hyde; AUC, area under the plasma concentration x time curve;
Cm , peak plasma concentration; t , time to reach peak plasma
concentration; PB, phenobarbital; DEX, dexamethasone; MTP,
metyrapone, ORP, orphenadrine; TAO, troleandomycin.
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